BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies

Biotech investors and healthcare innovators: BioVie, a clinical-stage company developing drug therapies for chronic conditions like liver disease and neurodegenerative disorders, has closed its $12 million public offering.

📌 Key Highlights:

6 million units sold, each with 1 share & 1 warrant

Units priced at $2 each

Partial over-allotment exercised: 667,000 warrants

Funds to support development of therapies for liver and neurological diseases

This capital raise strengthens BioVie’s position to advance innovative treatments for debilitating conditions.

🔖 YouTube Tags:
#BioVie #BiotechInvesting #PublicOffering #LiverDiseaseResearch #NeurologicalDisorders #NeurodegenerativeDiseases #BiotechFunding #HealthcareInnovation #DrugDevelopment #StockMarketNews #NewsOut #JaneKing #ClinicalStageBiotech #Biopharma